OBJECTIVE： To systematically review the efficacy of Compound danshen dripping pill or Compound danshen tablets for chronic hepatitis B complicated with hepatic fibrosis，and to provide evidence-based reference for clinical treatment. METHODS： Retrieved from PubMed， Cochrane Library， EMBase， Medline， Wanfang database， VIP， CJFD and CBM database， randomized controlled trials （RCTs） about Compound danshen dripping pills or tablets combined with entecavir（trial group） vs. entecavir alone （control group） for chronic hepatitis B complicated with hepatic fibrosis were collected. Meta-analysis was performed by using Rev Man 5.3 statistical software after data extraction and quality evaluation according to Cochrane systematic evaluation manual 5.1.0. RESULTS： A total of 9 RCTs were enrolled， including 714 patients. The results of Meta-analysis showed that ALT [SMD＝－0.44，95％CI（－0.86，－0.01），P＝0.04]， HA [SMD＝－1.53，95％CI（－2.28，－0.79），P＜0.001]， LN [SMD＝－0.93，95％CI（－1.41，－0.46），P＜0.001]， CⅣ [SMD＝－1.38，95％CI（－2.13，－0.63），P＜0.001] and PCⅢ [SMD＝－1.42，95％CI（－1.60，－1.23），P＜0.001] of trial group were significantly lower than those of control group； HBV-DNA negative rate [OR＝3.73，95％CI（2.14，6.49），P＜0.001] was significantly higher than control group， with statistical significance. CONCLUSIONS： Compound danshen dripping pills or tablets can not only improve liver function and liver fibrosis in chronic hepatitis B patients with hepatic fibrosis， but also improve the antiviral effect．